Kornimate/medical-research-clean huggingface dataset:
association of ex vivo drug response (evdr) and clinical outcome in ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: excyte-1 is a multicentre, prospective observational study to investigate the relationship between ex vivo drug response (evdr), measured in ovarian tumour-derived samples using high content imaging, and actual patient clinical response. patients with newly diagnosed or relapsed/refractory epithelial ovarian carcinoma, that present with malignant effusions (ascites or pleural effusions), will be enrolled in the study before starting their initial or next treatment line. enrolled patients will be asked to provide ascites, peripheral blood and fresh tumour tissue if available. samples will be shipped to the sponsor laboratory and their response to standard of care drugs evaluated ex vivo. participants will: * provide samples during routine clinical procedures * agree that data about their medical history, diagnosis and health status at the following timepoints are collected: at signature of the consent form, at the time samples are provided, at start of the therapy, upon completion of the therapy, regularly after completion of the therapy


Eligibility criteria:
inclusion criteria: * minimum age 18 years * signed informed consent form * confirmed diagnosis of ovarian cancer except low grade serous, clear cell and mucinous histology * where patients are treatment naïve, patients need to have disease stage figo (international federation of gynecology and obstetrics) iii or figo iv. * patient is expected to receive primary chemotherapy/maintenance after initial surgical debulking or a further line of systemic therapy in the relapsed setting according to treatment guidelines * feasibility of collecting malignant ascites and/or pleural effusion during either primary debulking surgery or a routine drainage procedure prior to initiation of the first or next line of systemic therapy * ecog (eastern cooperative oncology group) stage 0-2 exclusion criteria: * previously study participation * known or suspected hiv or active hepatitis b and/or c infection or active covid-19 infection * anticancer treatment or radiation therapy of the region which is to be drained or biopsied within the last 4 weeks * patient unfit or not willing to receive any further systemic treatment * patient is treated with therapeutics not tested in the assay - with the exception of anti-vegf (vascular endothelial growth factor) therapy * known pregnancy * sample quality criteria are not met (at least 250ml of ascites available, no signes of bacterial superinfection, no additives, at least 1% epcam (epithelial cell adhesion molecule) positive cells, viability at least 60%)
pregabalin versus levetiracetam in partial seizures

Conditions: Partial Seizures

Summary: this study will compare pregabalin and levetiracetam in patients with partial seizures. it will also evaluate the safety and tolerability of pregabalin and levetiracetam in these patients.


Eligibility criteria:
inclusion criteria: * subjects (male or female) must be \> 18 years of age, with a diagnosis of epilepsy with partial seizures, as defined in the international league against epilepsy (ilae) classification of seizures. * partial seizures may be simple or complex, with or without secondary tonic-clonic generalization. * subjects must be have been diagnosed with epilepsy for at least 2 years, and must have been unresponsive to treatment with at least two but no more than five prior antiepileptic drugs (aeds), and at the time of study enrollment are on stable dosages of 1 or 2 standard aeds. exclusion criteria: * females who are pregnant, breastfeeding, or intend to become pregnant during the course of the trial will be excluded * subjects with other neurologic illness that could impair endpoint assessment, or subjects with lennox-gastaut syndrome, absence seizures, status epileptics within the 12 months prior to trial entry, or with seizures due to an underlying medical illness or metabolic syndrome, will be excluded.

Keywords: epilepsies partial partial seizure disorder complex partial seizure disorder epilepsy
summative usability study of ciprofloxacin dry powder for inhalation using placebo

Conditions: Bronchiectasis; Pulmonary Disease, Chronic Obstructive

Summary: the rationale of this study is to conduct a summative (i.e., validation) usability test of ciprofloxacin dry powder for inhalation (dpi) and the associated instructions for use.


Eligibility criteria:
inclusion criteria * subjects (male and female) with non-cystic fibrosis bronchiectasis (ncfb) or chronic obstructive pulmonary disease (copd) * subjects must be aged ≥40 * subject must be able to independently manage and administer their ncfb/copd medications exclusion criteria: * subjects with recent exacerbation * subjects with recent significant hemoptysis in the four weeks before screening (and/or during the screening period) * subjects allergic to quinine * known chronic bronchial asthma

Keywords: usability test
video-interpreting in an emergency trauma room setting - a feasibility trial

Conditions: Communication Barriers

Summary: background: global migration increases the likelihood of language barriers. in medical situations language barriers have a negative effect on quality of treatment and thus endanger patient safety. in-hospital settings feasibility of video-translation has been demonstrated, yet there is lack of evidence in emergency trauma rooms. there, the physicians have to deal with time-critical decisions. aims: this feasibility trial aims to investigate technical feasibility, usability as well as the impact on decision-making (e.g. alteration of treatment strategies). methods: in this study 50 responsive patients with language barriers will be included. the anesthesiologic emergency physician will start video-translation via a tablet. feasibility, quality of communication, usability as well as changes in diagnosis and treatment will be gathered and analyzed.


Eligibility criteria:
inclusion criteria: * adult patients, at least 18 years old * awake, responsive patients * language barrier (albanian, dari, romanian, turkish, modern standard arabic, arabic, farsi, russian, hungarian, bosnian-croatian-serbian, kurdish (kurmanci), slovakian, bulgarian, polish, and czech) exclusion criteria: * unconscious patients * cardiac arrest patients * delay of treatment due to e-translation * refusal of video-translation by the patient

Keywords: communication barriers language barriers video-interpreting emergency medicine emergency physician
temporal discounting delayed outcomes on opioid-dependent outpatients - 20

Conditions: Opioid-Related Disorders

Summary: the purpose of this study is to assess the degree in which opioid-dependent outpatients discount the value of an additional maintenance dose of buprenorphine under differing states of opioid deprivation.


Eligibility criteria:
please contact site for information.
diagnostic pilot study of dual energy absorptiometry in the detection of osteopenia or osteoporosis in patients with thalassemia major

Conditions: Osteoporosis; Thalassemia Major; Osteopenia

Summary: objectives: i. determine the frequency and severity of osteopenia and osteoporosis in patients with thalassemia major who undergo dual energy x-ray absorptiometry, and correlate these findings with other relevant endocrinologic measurements.

protocol outline: patients undergo dual energy x-ray absorptiometry for bone density measurements, height (sitting and standing) and weight measurements, comprehensive endocrinologic examination, and assessment of the severity of iron overload at baseline, and then at years 1 and 2.

Eligibility criteria:
* diagnosis of thalassemia major with iron overload * not pregnant * negative pregnancy test

Keywords: disease-related problem/condition genetic diseases and dysmorphic syndromes hematologic disorders osteoporosis rare disease thalassemia major
pulmonary vasculopathy under second-line therapy of chronic myeloid leukemia

Conditions: Chronic Myeloid Leukemia

Summary: chronic myelogenous leukemia (cml) is a chronic myeloproliferative disorder characterized by a translocation between chromosome 9 and 22, leading to a pathogenic tyrosine kinase signal transduction protein. cml can be treated with tyrosine kinase inhibitors (tkis), which inhibit bcr/abl kinase, such as imatinib. in about 20% of cml patients who are treated by imatinib, a complete cytogenetic response cannot be achieved. the other two novel tkis (dasatinib and nilotinib), achieve higher rates of complete cytogenetic response and they are proposed as second-line therapy for imatinib-resistant patients or for those who do not tolerate imatinib. dasatinib inhibits bcr/abl kinase in about \>300 times in vitro in more than imatinib and also inhibits several other kinases, including the src family. src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. imatinib and nilotinib do not inhibit the src. incident cases of precapillary ph have been reported in patients who have cml treated with the dasatinib. improvements were usually observed after withdrawal of dasatinib. this study is designed to identify incident cases of dasatinib-associated ph and describe pulmonary vascular changes induced by dasatinib. as comparison population will be patients who receive another second-line tki (nilotinib).

doppler echocardiography at rest will be performed in each patient. patients without exercise capacity limitation an exercise test (doppler echocardiography with spiroergometry) will be performed. patients who show elevated spap at rest or during exercise (in this study spap ≥ 40 mmhg) or with reduced exercise capacity (peak vo2 \< 75%) a right heart catheterization (rhc) will be suggested. additionally for the evaluation of exercise capacity a 6 mwd will be performed. this work- up of patients allows clinical and hemodynamic evaluation.

Eligibility criteria:
inclusion criteria: * patients with chronic myeloid leukemia under second-line therapy with dasatinib or nilotinib * written informed consent exclusion criteria: * manifest pulmonary hypertension * significant pulmonary disease * left-sided heart failure or diastolic compliance dysfunction + * hemodynamic relevant valvular disease * systemic arterial hypertension (at rest systolic \>150 mmhg, diastolic \> 90 mmhg, during exercise \> 220 mmhg) * severe anemia * uncontrolled supraventricular and ventricular arrhythmias * myocardial infarction (within the last 12 months) * pulmonary embolism (within the last 12 months) * recent therapy changes (within the last 12 months) * recent major surgeries (within the last 12 months) * for exercise tests: musculoskeletal diseases which may unable the exercise tests.

Keywords: pulmonary hypertension chronic myeloid leukemia dasatinib nilotinib
comparison of efficacy of bupivacaine for relief postoperative pain in women undergoing laparoscopic gynecologic surgery

Conditions: Postoperative Pain Score

Summary: to comparison of efficacy of bupivacaine for relief postoperative pain in women undergoing laparoscopic gynecologic surgery

gynecologic laparoscopic procedures have become more common nowadays because of their benefits in less tissue trauma, less perioperative morbidity and shorter hospital stays compared with laparotomy. but postoperative pain still be the most concerning problems including discomfort at incision sites, pain due to pneumoperitoneum stretching the intraabdominal cavity and dissection of the abdominal and pelvic viscera. visceral pain is at maximal intensity during the first postoperative hours and is exacerbated by coughing, respiratory movements, and mobilization. because the pain comprises of several factors, multimodal analgesic techniques are needed for effective postoperative analgesia and brought to this study to compare efficacy of bupivacaine for pain relief postoperatively in women undergoing gynecologic laparoscopic surgery divided into 4 groups including preincision and preclosure bupivacaine injection collated with placebo group. the result is measurement in postoperative pain score and amount of drug that using to reduce pain

Eligibility criteria:
inclusion criteria: * patient who undergoing gynecologic laparoscopic surgery * patient who agrees to participate in this study * patient able to speak and understand thai * patient able to complete the questionnaire exclusion criteria: * patient with history of allergy in any kind anesthetic drug * patient who pregnant * patient who sign for single port gynecologic laparoscopic surgery or note surgery * patient whom the surgery is withhold or canceled * patient whom the surgery is converted to laparotomy

Keywords: bupivacaine, port site infiltration ,postoperative pain ,gynecologic laparoscopy
a study evaluating the efficacy of fluocinonide cream 0.1% (vanos) in subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this research study is to better understand how fluocinonide cream 0.1% (vanos®) works when people use it to treat atopic dermatitis for just a few days.

this is a single center study. this is an open label study of fluocinonide cream 0.1% (vanos™) for subjects with mild to severe atopic dermatitis with an assessment of 2 to 4 on the investigator global assessment scale (appendix b). up to 20 subjects age 12 and above will be enrolled after providing informed consent. all subjects will receive the study medication, fluocinonide cream 0.1% (vanos™). each subject will be instructed to use fluocinonide cream 0.1% (vanos™) twice daily for three consecutive days (for a total of 6 doses). the study period will last for approximately 2 weeks. subjects will be evaluated at baseline and day 2 or 3 (as needed to achieve 6 doses), day 7 and day 14 (or end of study). subjects will not apply any study drug after the 6 doses.

Eligibility criteria:
inclusion criteria: * male or female with mild to severe atopic dermatitis, 12 years of age or older, that agree to participate and provide written consent (and assent if applicable) * have an investigator global assessment of mild to severe atopic dermatitis (iga rating of 2 - 4 in the investigator global assessment (appendix b)) * percentage of overall body surface are of involvement (bsa) must be ≥2% * women of child bearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control exclusion criteria: * use within 4 weeks of baseline of systemic anti-inflammatory medication, which may influence study outcome, such as systemic corticosteroids * application or use within 2 weeks of baseline of topical corticosteroid medications or topical anti-inflammatory medication, which may influence study outcome * presence of a concurrent medical condition, which is determined by the investigator to potentially interfere with study outcomes or patient assessments * introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study * amount of disease involvement that would require \>60 gm of cream in a 1 week period * subjects with known allergy or sensitivity to topical vanos™ cream or components * pregnant women and women who are breastfeeding are to be excluded. women of childbearing potential will be allowed to participate in the study, and these subjects will be required to use at least one form of birth control.

Keywords: atopic dermatitis open-label topical cream eczema vanos
muscle ultrasound study in shock patients

Conditions: Septic Shock

Summary: intensive care unit (icu) patients are known to lose muscle mass and function for many reasons, ranging from prolonged immobilization, to the effects of icu treatments such as mechanical ventilation (mv), to the critical illness itself. ultrasonography (us) is widely used in the icu setting and has greatly evolved in the last decades, since it allows the non-invasive assessment of different structures, using radiation-free and user-friendly technology; its application for the assessment or the skeletal muscle is a promising tool and might help detecting muscle changes and thus several dysfunctions during early stages of icu stay. by using skeletal muscle ultrasound at both diaphragm and peripheral levels, the overall aim of this study is to improve knowledge in the early detection of muscle dysfunction and weakness , and their relationship with mechanical ventilation weaning and muscle strength, in critically ill patients suffering from septic shock.


Eligibility criteria:
inclusion criteria: 1. adult patients (\> 18 years old) admitted to the icu 2. with a diagnosis of septic shock 3. a sofa score equal or superior to 8 points, at icu admission 4. blood lactate concentration above 2 mmol/l, at icu admission 5. expected to have more than 48h of mechanical ventilation (estimated by the attending physician) 6. expected to stay more than 5 days in the unit (estimated by the attending physician) 7. able to walk prior to icu admission / walking aids accepted; exclusion criteria: 1. pregnancy 2. lower limb amputation, fixators or open wounds 3. thoracic fixators or open wounds 4. diagnosed neuromuscular or central nervous system diseases 5. being transferred from another icu 6. spinal cord injury 7. diaphragm pacemaker 8. palliative goals of care 9. cancers derived sarcopenia 10. cachexia 11. anorexic disorders (protein-energy malnutrition) 12. intellectual or cognitive impairments, limiting the ability to follow instructions.

Keywords: muscle ultrasound intensive care unit-acquired weakness diaphragm dysfunction mechanical ventilation weaning sepsis critical illness
effects of proximal and distal robot-assisted therapy combined with functional training

Conditions: Stroke

Summary: the purpose of this study is to compare the training effects of robot-assisted therapy focus on proximal part, distal part, or total segment of upper extremity, respectively.


Eligibility criteria:
inclusion criteria: * unilateral stroke that verified by ct scan * time since stroke more than 6 months * moderate and mild upper limb motor impairment identified from the ue subtest of fma range from 10 to 50 * mini-mental state examination (mmse) more than 24 points is needed to follow commands exclusion criteria: * serious visual or visual perception problems * orthopedic or other neurological problems occurred in recent 6 months * attend any other study in recent 3 months

Keywords: stroke rehabilitation robot-assisted therapy
staging of superficial eac using vle

Conditions: Esophageal Cancer

Summary: this study is being done to see if the nvisionvle imaging system can accurately determine the diagnostic performance of staging of t1 esophageal adenocarcinoma.

volumetric laser endomicroscopy (vle) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution. vle has been used to detect dysplasia associated with barrett's esophagus (be) but its use in cancer staging has not been previously explored. the investigators propose that vle can accurately and comprehensively stage t1 eac. vle scans will be analyzed using an automated computer algorithm to measure degree of signal attenuation over areas demarcated for endoscopic mucosal resection (emr). the signal attenuation cut-off established will be used to classify cancers as superficial versus deep. emr specimens will be reviewed histopathologically for grade of tumor differentiation, depth of invasion, and presence or absence of lymphovascular invasion. depth of tumor invasion will be measured and used to classify cancers as superficial versus deep.

Eligibility criteria:
inclusion criteria: * patient over the age of 18 * patient undergoing an upper endoscopy with prior-biopsy confirmed barrett's esophagus. * ability to provide written, informed consent * no significant esophagitis (la grade \<b, c, and d) exclusion criteria: * patients who have achieved complete remission of intestinal metaplasia (cr-im) * patients without visible barrett's esophagus at the time of study esophagogastroduodenoscopy (egd) * patients for whom use of the nvisionvle device would be in conflict with the instruction for use. * prior esophageal or gastric surgical resection * significant esophageal stricture requiring dilatation * patients who require anticoagulation for who biopsy would be contraindicated * patients who are known to be pregnant
investigation of autonomic dysfunction in patients with familial mediterranean fever

Conditions: Familial Mediterranean Fever; Autonomic Dysfunction

Summary: familial mediterranean fever (fmf) is the most common inherited autoinflammatory disease affecting 150,000 patients worldwide. periodic febrile exacerbations, peritonitis, and pleuritis are characteristic disease features. dysregulation of il-1β secretion has an important role in the pathophysiology of the disease, and il-1β also serves as a therapeutic target. chronic inflammation has been associated with early atherosclerotic and cardiovascular disease in various rheumatic diseases. an increased risk for cardiovascular events associated with disease activity has been described in rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. in addition, autonomic nervous system dysfunction may contribute to increased cardiovascular risk in patients with inflammatory disease. for example, decreased heart rate variability is an important feature of cardiac autonomic dysfunction and is an isolated risk factor for cardiovascular events. autonomic dysfunction studies related to fmf have conflicting results. the aim of this study was to determine autonomic dysfunction symptoms and objective findings in patients with fmf; demographic characteristics, disease characteristics, inflammatory burden, fatigue level, sleep quality, presence of fibromyalgia and their relationship with quality of life were evaluated and compared with healthy controls.


Eligibility criteria:
inclusion criteria: familial mediterranean fever group; 1. being between the ages of 18-65 2. having a definite diagnosis of familial mediterranean fever according to livneh criteria healthy control group; 1. being between the ages of 18-65 2. absence of any disease diagnosis exclusion criteria: 1. liver or kidney failure 2. pregnancy 3. diabetes mellitus 4. thyroid diseases 5. those who use neuroprotective or antihypertensive drugs 6. vitamin b12 deficiency 7. anemia 8. paraneoplastic neuropathy 9. alcoholism 10. cardiac failure 11. cardiac arrhythmia 12. acute thrombosis 13. having a diagnosis of another systemic rheumatic disease 14. persons who did not give consent to participate in the study

Keywords: familial mediterranean fever autonomic dysfunction r-r interval variability sympathetic skin response
clinical & biochemical effect of atorvastatin in nano particles gel in periodontitis treatment

Conditions: Periodontitis

Summary: periodontitis is a destructive chronic inflammatory disease characterized by periodontium damage and pocket formation between the tooth and the gingival margin resulting in ultimate tooth loss. various topical anti-inflammatory drugs were used to treat inflammation in periodontitis. introducing atorvastatin as a novel remedy for periodontitis treatment necessitates developing a syringeable modified delivery system capable of targeting inflammation within the periodontal pockets.


Eligibility criteria:
inclusion criteria: * systemically healthy patients * patients with moderate periodontitis exclusion criteria: * pregnant women * lactating women * patients with chronic diseases

Keywords: periodontitis non-surgical treatment atorvastatin phase 1 therapy